SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Section 1: Identification

Product name: Peginterferon Alfa-2b Powder Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone: 908-740-4000
Emergency telephone number: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

Section 2: Hazard identification

GHS Classification
Reproductive toxicity: Repr.1B

GHS label elements
Hazard pictograms:

Signal word: Danger
Hazard statements: H360FD May damage fertility. May damage the unborn child.
Precautionary statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P281 Use personal protective equipment as required.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Version 5.1  Revision Date: 09/13/2019  SDS Number: 20536-00017  Date of last issue: 03.05.2019  Date of first issue: 09.10.2014

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chemical name</td>
</tr>
<tr>
<td></td>
<td>Sucrose</td>
</tr>
<tr>
<td></td>
<td>Peginterferon Alfa-2b</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May damage fertility. May damage the unborn child.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire-fighting: Avoid generating dust; fine dust dispersed in air in sufficient
## Section 6: Accidental release measures

| Personal precautions, protective equipment and emergency procedures | Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations. |
| Environmental precautions | Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained. |
| Methods and materials for containment and cleaning up | Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

## Section 7: Handling and storage

| Technical measures | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | If sufficient ventilation is unavailable, use local exhaust ventilation. |
| Advice on safe handling | Do not get on skin or clothing. Do not breathe dust. |
Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

### Section 8: Exposure controls/personal protection

#### Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td>Peginterferon Alfa-2b</td>
<td>215647-85-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

#### Engineering measures: Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust ventilation.

#### Personal protective equipment

**Respiratory protection:** If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type:** Particulates type

**Hand protection material:** Chemical-resistant gloves
Remarks: Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection: Wear the following personal protective equipment: Safety goggles

Skin and body protection: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Section 9: Physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>White to light yellow</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>1 g/cm3</td>
</tr>
</tbody>
</table>
Water solubility: No data available
Partition coefficient: n-octanol/water: No data available
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity
  Viscosity, dynamic: No data available
  Viscosity, kinematic: No data available
Explosive properties: Not explosive

Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available

Section 10: Stability and reactivity
Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
  May form explosive dust-air mixture during processing, handling or other means.
  Can react with strong oxidizing agents.
Conditions to avoid: Heat, flames and sparks.
  Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

Section 11: Toxicological information
Exposure routes:
  Inhalation
  Skin contact
  Ingestion
  Eye contact

Acute toxicity
Not classified based on available information.

Components:
Sucrose:
  Acute oral toxicity: LD50 (Rat): 29,700 mg/kg

Peginterferon Alfa-2b:
  Acute toxicity (other routes of administration): LD50 (Rat): > 20.1 mg/kg
  Application Route: Intravenous
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Version 5.1  Revision Date: 09/13/2019  SDS Number: 20536-00017  Date of last issue: 03.05.2019
Date of first issue: 09.10.2014

LD50 (Monkey): > 9.8 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Peginterferon Alfa-2b:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Peginterferon Alfa-2b:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Sucrose:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Peginterferon Alfa-2b:
Genotoxicity in vitro: Test Type: reverse mutation assay
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo:
Species: Mouse
Result: negative
Carcinogenicity
Not classified based on available information.

Reproductive toxicity
May damage fertility. May damage the unborn child.

Components:

Peginterferon Alfa-2b:
Effects on fertility:
Test Type: Fertility/early embryonic development
Species: Monkey, female
Application Route: Subcutaneous
Dose: 0.35 milligram per kilogram
Symptoms: Effect on estrous cycle

Reproductive toxicity - Assessment:
Clear evidence of adverse effects on development, based on animal experiments. Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Peginterferon Alfa-2b:
Target Organs:
Gastrointestinal tract, Immune system, Cardio-vascular system, Endocrine system, Central nervous system, Liver, Respiratory Tract, Eye
Assessment:
Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity
Components:

Peginterferon Alfa-2b:
Species:
Mouse
NOAEL:
0.0038 mg/kg
Application Route:
Subcutaneous
Exposure time:
9 d

Species:
Rat
NOAEL:
0.0042 mg/kg
Application Route:
Subcutaneous
Exposure time:
30 d

Species:
Monkey
LOAEL:
0.12 mg/kg
Application Route:
Subcutaneous
Exposure time:
30 d
Target Organs:
Blood, Bone marrow, Immune system
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Species: Monkey
NOAEL: 0.015 mg/kg
LOAEL: 0.077 mg/kg
Exposure time: 3 Months
Target Organs: Respiratory Tract, Cardio-vascular system, Central nervous system, Bone marrow

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Peginterferon Alfa-2b:
Inhalation: Symptoms: flu-like symptoms, Gastrointestinal disturbance, mental depression, tingling

Section 12: Ecological information

Ecotoxicity

Components:

Peginterferon Alfa-2b:

Ecotoxicology Assessment
Acute aquatic toxicity: No data available
Chronic aquatic toxicity: No data available

Persistence and degradability

Components:

Peginterferon Alfa-2b:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 63 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential

Components:

Sucrose:
Partition coefficient: n-octanol/water: Pow: < 1

Mobility in soil
No data available

Other adverse effects
No data available
Section 13: Disposal considerations

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
Not regulated as a dangerous good

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
not allocated

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Further information

Date format : dd.mm.yyyy
SAFETY DATA SHEET

Peginterferon Alfa-2b Powder Formulation

Version 5.1
Revision Date: 09/13/2019
SDS Number: 20536-00017
Date of last issue: 03.05.2019
Date of first issue: 09.10.2014

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average
NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.